Eliem Therapeutics (ELYM) News Today → America could fall from this event (From Porter & Company) (Ad) Free ELYM Stock Alerts $8.41 -0.05 (-0.59%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11 at 11:34 PM | marketbeat.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest UpdateEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 56,700 shares, a decline of 90.6% from the April 15th total of 601,100 shares. Currently, 0.3% of the company's stock are short sold. Based on an average daily volume of 825,000 shares, the short-interest ratio is presently 0.1 days.April 25, 2024 | marketbeat.comShort Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Increases By 4,453.8%Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Currently, 3.3% of the company's stock are short sold. Based on an average trading volume of 665,800 shares, the short-interest ratio is currently 0.9 days.April 24, 2024 | marketbeat.comBML Capital Management LLC Boosts Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)BML Capital Management LLC boosted its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 12.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,180,000 shares of the compApril 23, 2024 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Trading 0.5% Higher Eliem Therapeutics (NASDAQ:ELYM) Shares Up 0.5%April 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmApril 12, 2024 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 11, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODNApril 11, 2024 | finance.yahoo.comEliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines DealApril 11, 2024 | msn.comEnlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare moversApril 11, 2024 | markets.businessinsider.comEliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-marketApril 11, 2024 | businesswire.comELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to ShareholdersApril 11, 2024 | globenewswire.comEliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 5, 2024 | msn.comELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023March 6, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn SituationFebruary 18, 2024 | marketbeat.comSilverarc Capital Management LLC Lowers Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)Silverarc Capital Management LLC trimmed its holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 75.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,110 shares of the company's stock after sellingFebruary 3, 2024 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Shares Up 3.5%Eliem Therapeutics (NASDAQ:ELYM) Trading Up 3.5%November 19, 2023 | morningstar.comCheckpoint Therapeutics Inc CKPTNovember 15, 2023 | morningstar.comEliem Therapeutics Inc ELYMSeptember 28, 2023 | finance.yahoo.comEliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJuly 21, 2023 | finance.yahoo.comEliem (ELYM) to Explore Strategic Options, Stock Rises 6%July 21, 2023 | msn.comEliem Therapeutics’ stock soars 21% premarket after company says it may sell itselfJuly 20, 2023 | benzinga.comWhat's Happening With Eliem Therapeutics Shares Today?July 20, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic AlternativesJuly 20, 2023 | marketwatch.comEliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYMJuly 20, 2023 | markets.businessinsider.comWhy Is Eliem Therapeutics (ELYM) Stock Up 6% Today?July 20, 2023 | finance.yahoo.comEliem Therapeutics Announces Plans to Explore Strategic AlternativesJune 7, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)May 25, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)May 12, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business HighlightsMay 11, 2023 | seekingalpha.comEliem Therapeutics GAAP EPS of -$0.84May 11, 2023 | finance.yahoo.comEliem Therapeutics Reports First Quarter Financial Results and Business HighlightsMay 5, 2023 | marketbeat.comTrading was temporarily halted for "ELYM" at 10:05 AM with a stated reason of "LULD pause."April 21, 2023 | finance.yahoo.comWe're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash WiselyMarch 9, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)March 7, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsMarch 6, 2023 | finance.yahoo.comEliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsFebruary 23, 2023 | seekingalpha.comELYM Eliem Therapeutics, Inc.February 23, 2023 | finance.yahoo.comEliem Therapeutics slashing staff amid leadership shakeupFebruary 18, 2023 | finance.yahoo.comEliem Pauses Development On Depression Drug, Lays Off 55% WorkforceFebruary 10, 2023 | msn.comEliem Therapeutics down after announcing reprioritization plans, layoffsFebruary 9, 2023 | finance.yahoo.comEliem Therapeutics Provides Strategic Update and Announces Leadership TransitionFebruary 9, 2023 | marketbeat.comTrading was temporarily halted for "ELYM" at 04:02 PM with a stated reason of "News pending."February 6, 2023 | marketbeat.comTrading was temporarily halted for "ELYM" at 09:02 AM with a stated reason of "LULD pause." Trading set to resume at 09:02 AM. November 30, 2022 | finance.yahoo.comEliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual ConferenceNovember 14, 2022 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Third Quarter Financial and Business HighlightsNovember 12, 2022 | finance.yahoo.comIs Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth?November 8, 2022 | finance.yahoo.comEliem Therapeutics to Participate at Two Upcoming Investor ConferencesAugust 18, 2022 | seekingalpha.comEliem Therapeutics (ELYM) Investor Presentation - SlideshowAugust 15, 2022 | msn.comEliem Therapeutics: Q2 Earnings InsightsAugust 15, 2022 | finance.yahoo.comEliem Therapeutics Reports Second Quarter Financial and Business Highlights Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this chart look familiar? (Ad)Investors who understand when to get in — and when to get out… Can make a lot of money. Like in the chart, I showed you above… Get all the information here. ELYM Media Mentions By Week ELYM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELYM News Sentiment▼1.600.57▲Average Medical News Sentiment ELYM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELYM Articles This Week▼30▲ELYM Articles Average Week Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RAPT Therapeutics News Inozyme Pharma News XOMA News XBiotech News Xeris Biopharma News CytomX Therapeutics News Enanta Pharmaceuticals News Verastem News Nektar Therapeutics News Akebia Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELYM) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressNo experience to confident trader, meet my student…Wealth Builders InstituteThe only AI company you should be looking atBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
